Use of kukoamine a and kukoamine b

Abstract

The use of Kukoamine A and Kukoamine B in the preparation of drugs for the prevention and treatment of sepsis and autoimmune disease is disclosed. Bacterial endotoxin/lipopolysaccaride (LPS) and unmethylated DNA (CpG DNA) of bacteria, the major pathogen-associated molecular patterns in sepsis and autoimmune disease, are specifically targeted, while the disclosed use directionally isolates lead compounds from traditional Chinese medicine. These measures can overcome the major defects of uncertainty of pharmacological material basis and drug targets of extracts and constituents of traditional Chinese medicine. The disclosed use can help in developing a safe, effective and quality controllable drug for prevention and treatment of sepsis and autoimmune disease so as to help solve the present lack of effective drugs in clinical treatment.

1 . Use of Kukoamine A and Kukoamine B in the preparation of drugs for the prevention and treatment of sepsis and autoimmune disease. 
     
     
         2 . The use of  claim 1  wherein said Kukoamine A and Kukoamine B are extracted from  Lycii cortex  of traditional Chinese medicine. 
     
     
         3 . The use of  claim 2  wherein said  Lycii cortex  is the dried root bark of  Lycium chinese  Mill. or  Lycium barbarum  L of the Solanaceae family. 
     
     
         4 . The use of  claim 1  wherein said drugs are used for the preparation of drugs for the prevention and treatment of sepsis and autoimmune disease. 
     
     
         5 . The use of  claim 1  wherein said drugs are used for antagonizing the key factors that lead to sepsis and autoimmune disease, bacterial endotoxin/lipopolysaccharide (LPS) and unmethylated DNA (CpG DNA) of bacteria. 
     
     
         6 . A pharmaceutical composition comprising Kukoamine A and Kukoamine B for use in the prevention and treatment of sepsis and autoimmune disease. 
     
     
         7 . The pharmaceutical composition of  claim 6  wherein said Kukoamine A and Kukoamine B are extracted from  Lycii cortex  of traditional Chinese medicine. 
     
     
         8 . The pharmaceutical composition of  claim 7  wherein said  Lycii cortex  is the dried root bark of  Lycium chinese  Mill. or  Lycium barbarum  L of the Solanaceae family. 
     
     
         9 . The pharmaceutical composition of  claim 6  wherein said drugs are used for the preparation of drugs for the prevention and treatment of sepsis and autoimmune disease. 
     
     
         10 . The pharmaceutical composition of  claim 6  wherein said drugs are used for antagonizing the key factors that lead to sepsis and autoimmune disease, bacterial endotoxin/lipopolysaccharide (LPS) and unmethylated DNA (CpG DNA) of bacteria.